Fulgent Genetics Stock Forecast, Price & News

Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

Is Fulgent Genetics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics or view top-rated stocks.

What stocks does MarketBeat like better than Fulgent Genetics?

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a drop in short interest in August. As of August 13th, there was short interest totaling 3,850,000 shares, a drop of 14.3% from the July 29th total of 4,490,000 shares. Based on an average daily trading volume, of 754,000 shares, the short-interest ratio is currently 5.1 days. Currently, 20.2% of the company's stock are sold short.
View Fulgent Genetics' Short Interest.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Fulgent Genetics.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Monday, August, 9th. The company reported $2.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.54 by $0.07. The firm had revenue of $153.60 million for the quarter, compared to analysts' expectations of $197.34 million. Fulgent Genetics had a trailing twelve-month return on equity of 78.71% and a net margin of 54.24%. The business's quarterly revenue was up 789.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 EPS.
View Fulgent Genetics' earnings history.

How has Fulgent Genetics' stock price been impacted by Coronavirus?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLGT stock has increased by 747.3% and is now trading at $85.24.
View which stocks have been most impacted by COVID-19.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its third quarter 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125 million-$150 million, compared to the consensus revenue estimate of $146.10 million.

What price target have analysts set for FLGT?

4 brokerages have issued 1 year price targets for Fulgent Genetics' stock. Their forecasts range from $65.00 to $140.00. On average, they expect Fulgent Genetics' stock price to reach $111.67 in the next year. This suggests a possible upside of 31.0% from the stock's current price.
View analysts' price targets for Fulgent Genetics or view top-rated stocks among Wall Street analysts.

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:

• Ming Hsieh, Chairman, President & Chief Executive Officer
• James Xie, Chief Operating Officer
• Paul H. Kim, Chief Financial Officer
• Harry Gao, Chief Scientific Officer & Laboratory Director
• Lawrence M. Weiss, Chief Medical Officer

Who are some of Fulgent Genetics' key competitors?

Some companies that are related to Fulgent Genetics include Invitae (NVTA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), CareDx (CDNA), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL), Renalytix AI (RNLX), Sera Prognostics (SERA), Celcuity (CELC), Exagen (XGN) and Centogene (CNTG).
View all of FLGT's competitors.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.54%), Vanguard Group Inc. (4.41%), State Street Corp (2.10%), Susquehanna International Group LLP (0.00%), Morgan Stanley (1.25%) and Morgan Stanley (1.23%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics.

Which institutional investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Morgan Stanley, Citadel Advisors LLC, Russell Investments Group Ltd., Millennium Management LLC, Marshall Wace LLP, and Marshall Wace LLP. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics or view top insider-selling stocks.

Which institutional investors are buying Fulgent Genetics stock?

FLGT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., JPMorgan Chase & Co., State Street Corp, Capital Fund Management S.A., Geode Capital Management LLC, First Trust Advisors LP, and Skandinaviska Enskilda Banken AB publ.
View insider buying and selling activity for Fulgent Genetics or or view top insider-buying stocks.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $85.24.

How much money does Fulgent Genetics make?

Fulgent Genetics has a market capitalization of $2.52 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $8.85 on an earnings per share basis.

How many employees does Fulgent Genetics have?

Fulgent Genetics employs 429 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Where are Fulgent Genetics' headquarters?

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at (626) 350-0537 or via email at [email protected].